By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Recordati S.p.A 

Via M. Civitali, 1

Milan    20148  Italy
Phone: 39-02-487871 Fax: 39-02-40073747




Forest  Licensing agreement for the development of lercanidipine, a long-acting dihydropyridine calcium channel blocker for the treatment of hypertension.

Digital Gene Technologies  Atherosclerosis

Company News
Apricus Biosciences (APRI) Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Spain By Recordati S.p.A 5/6/2015 7:37:10 AM
Recordati S.p.A Finalizes The Second Tranche Of Its Acquisition Of Opalia Pharma In Tunisia 5/27/2014 9:37:15 AM
Prasco Laboratories Announces Authorized Generic Agreement With Recordati S.p.A 5/22/2014 9:35:51 AM
Recordati S.p.A: Sales Growth And Significant Margin Improvement In The First Quarter 2014 5/6/2014 9:13:51 AM
Recordati S.p.A: Shareholders Approve The 2013 Accounts. Dividend EU 0.33 Per Share 4/17/2014 9:43:43 AM
Gebro Pharma Signs A Licensing Agreement With Recordati S.p.A For The Commercialization Of Kentera® In Spain 2/27/2014 8:48:10 AM
Recordati S.p.A : Preliminary 2013 Results Show Significant Growth. Sales +13.7%, Ebit +17.0%, Net Income +12.8%. 2/11/2014 9:21:02 AM
Apricus Biosciences (APRI), Recordati S.p.A Forge Erectile Dysfunction Pact Worth $47 Million 2/10/2014 7:13:04 AM
Recordati S.p.A Board Of Directors Approves 2014 Objectives 1/16/2014 9:06:08 AM
Recordati S.p.A Buys Tunisia's Opalia Pharma for 37 Million Euros 7/25/2013 6:35:59 AM